3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
3
Glioma
3
Colorectal Neoplasms
3
Wilms Tumor
2
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
larotrectinib
×
Gastrointestinal
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA